ArticleApplied microbiology and biotechnology2026
Inhibiting biofilm growth on ammonium salt-functionalized or fluorinated voice prostheses silicone.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Voice prostheses (VPs) are largely limited by their relatively short functional lifespans, mainly due to colonization by heterogeneous fungal-bacterial biofilms. This biofilm-mediated degradation is a major contributor to VP failure and is associated with clinically significant complications such as impaired phonation, leakage through the tracheoesophageal fistula, and an increased risk of pneumonia. We performed a series of in vitro experiments to assess the antimicrobial and physicochemical properties of VPs constructed from quaternary ammonium salt-functionalized or fluorinated silicone. Biofilm development on each prosthesis was quantified by measuring crystal violet-stained biomass, and surface coverage was visualized using scanning electron microscopy. Furthermore, biofilm morphology and material adhesion characteristics were examined by atomic force microscopy. To evaluate cytocompatibility, fibroblasts were exposed to extracts obtained after 24 h incubation of each material in culture medium. This was followed by analysis of cell area, circularity index, haemolytic activity and cytokine secretion. Mechanical testing was performed to determine the physiochemical performance of the tested silicone materials. Crystal violet staining demonstrated substantial biofilm accumulation on VPs retrieved from patients after three months of use. In contrast, the modified silicone materials exhibited markedly reduced biofilm coverage. All tested materials supported normal fibroblast proliferation and showed minimal hemolytic activity, although they differed in their capacity to induce cytokine expression. Incorporation of ammonium salt-functionalised or fluorinated silicone in VP design may substantially reduce surface biofilm formation. Thereby, improving device longevity and decreasing the risk of use-related complications. Key points • Fluorinated and quaternary ammonium salt-modified silicones exhibit significant biofilm resistance. • The modified materials demonstrate established biocompatibility with human cells. • These findings suggest the potential for developing new, extended-lifespan voice prostheses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.